Pegfilgrastim Biosimilars in US Supportive Oncology: A Narrative Review of Administration Options and Economic Considerations to Maximize Patient Benefit
Crossref DOI link: https://doi.org/10.1007/s40487-022-00207-2
Published Online: 2022-09-16
Published Print: 2022-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Humphreys, Sophia Z.
Geller, Robert B.
Walden, Paul
Text and Data Mining valid from 2022-09-16
Version of Record valid from 2022-09-16
Article History
Received: 18 March 2022
Accepted: 24 August 2022
First Online: 16 September 2022